Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease

Bernardo Casso-Chapa; Norma Alicia Vazquez González; Nhat-Tu Le; Nicolas L. Palaskas; Kevin T. Nead; Lydia P. Eutsey; Venkata S.K. Samanthapudi; Abigail M. Osborn; Jonghae Lee; Gilbert Mejia; Oanh Hoang; Steven H. Lin; Anita Deswal; Joerg Herrmann; Guangyu Wang; James L. Kirkland; Sunil Krishnan; Xander H.T. Wehrens; Eduardo N. Chini; Syed Wamique Yusuf; Cezar A. Iliescu; Abhishek Jain; Jared K. Burks; Erin Seeley; Philip L. Lorenzi; Khanh M. Chau; Keila Carolina Ostos Mendoza; Isabella M. Grumbach; Paul S. Brookes; Nordin M.J. Hanssen; Menno P.J. de Winther; Laurent Yvan-Charvet; Sivareddy Kotla; Keri Schadler; Jun-ichi Abe

doi:10.1161/ATVBAHA.124.319870

Back

Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease

Journal article

Peer reviewed

Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease

Bernardo Casso-Chapa, Norma Alicia Vazquez González, Nhat-Tu Le, Nicolas L. Palaskas, Kevin T. Nead, Lydia P. Eutsey, Venkata S.K. Samanthapudi, Abigail M. Osborn, Jonghae Lee, Gilbert Mejia, …

Arteriosclerosis, thrombosis, and vascular biology, Vol.45(3), pp.372-385

03/2025

DOI: 10.1161/ATVBAHA.124.319870

PMCID: PMC11864897

PMID: 39817327

Files and links (1)

url

https://pure.amsterdamumc.nl/ws/files/138570638/Reevaluating-anti-inflammatory-therapy.pdfView

Open Access

Abstract

Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression. Anti-inflammatory therapy, therefore, presents a unique dilemma for cancer survivors: while it may decrease cardiovascular risk, it might also promote cancer growth and metastasis by suppressing the immune response. Senescence presents a potentially targetable solution to this challenge; senescence increases the risk of both cancer therapy resistance and vascular disease. Exercise, notably, shows promise in delaying this premature senescence, potentially improving cancer outcomes and lowering vascular disease risk post-treatment. This review focuses on the long-term impact of cancer therapies on vascular health. We underscore the importance of modulating senescence to balance cancer treatment’s effectiveness and its vascular impact, and we emphasize investigating the role of exercise-mediated suppression of senescence in improving cancer survivorship.

Cardiovascular Disease

Exercise

Immune System

Inflammation

cell proliferation

cellular senescence

neoplasms

Details

Title: Subtitle: Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease
Creators: Bernardo Casso-Chapa - The University of Texas MD Anderson Cancer Center
Norma Alicia Vazquez González - The University of Texas MD Anderson Cancer Center
Nhat-Tu Le - Houston Methodist
Nicolas L. Palaskas - The University of Texas MD Anderson Cancer Center
Kevin T. Nead - The University of Texas MD Anderson Cancer Center
Lydia P. Eutsey - The University of Texas MD Anderson Cancer Center
Venkata S.K. Samanthapudi - The University of Texas MD Anderson Cancer Center
Abigail M. Osborn - The University of Texas MD Anderson Cancer Center
Jonghae Lee - The University of Texas MD Anderson Cancer Center
Gilbert Mejia - The University of Texas MD Anderson Cancer Center
Oanh Hoang - The University of Texas MD Anderson Cancer Center
Steven H. Lin - The University of Texas MD Anderson Cancer Center
Anita Deswal - The University of Texas MD Anderson Cancer Center
Joerg Herrmann - Mayo Clinic
Guangyu Wang - Houston Methodist
James L. Kirkland - Cedars-Sinai Medical Center
Sunil Krishnan - The University of Texas Health Science Center at Houston
Xander H.T. Wehrens - Baylor College of Medicine
Eduardo N. Chini - Mayo Clinic in Florida
Syed Wamique Yusuf - The University of Texas MD Anderson Cancer Center
Cezar A. Iliescu - The University of Texas MD Anderson Cancer Center
Abhishek Jain - Texas A&M University
Jared K. Burks - The University of Texas MD Anderson Cancer Center
Erin Seeley - The University of Texas at Austin
Philip L. Lorenzi - The University of Texas MD Anderson Cancer Center
Khanh M. Chau - Houston Methodist
Keila Carolina Ostos Mendoza - The University of Texas MD Anderson Cancer Center
Isabella M. Grumbach - University of Iowa
Paul S. Brookes - University of Rochester
Nordin M.J. Hanssen - Amsterdam University Medical Centers
Menno P.J. de Winther - Amsterdam University Medical Centers
Laurent Yvan-Charvet - Inserm
Sivareddy Kotla - The University of Texas MD Anderson Cancer Center
Keri Schadler - The University of Texas MD Anderson Cancer Center
Jun-ichi Abe - The University of Texas MD Anderson Cancer Center
Resource Type: Journal article
Publication Details: Arteriosclerosis, thrombosis, and vascular biology, Vol.45(3), pp.372-385
DOI: 10.1161/ATVBAHA.124.319870
PMID: 39817327
PMCID: PMC11864897
NLM abbreviation: Arterioscler Thromb Vasc Biol
ISSN: 1079-5642
eISSN: 1524-4636
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Grant note: National Institutes of Health (NIH): HL-149303, AI-156921, HL-134740, HL-153350, HL-160992, HL157790 Cancer Prevention and Research Institute of Texas (CPRIT): RP190256 University of Texas MD Anderson Cancer Center Institutional Research Grant ProgramMD Anderson Cancer Center Support Grant: CA016672 National Cancer Institute's Research Specialist 1: R50 CA243707-01A1 Shared Instrumentation Award from the Cancer Prevention Research Institution of Texas (CPRIT): RP121010 US NIH: R37AG013925, R33AG061456 Hevolution Foundation: HF-GRO 1199148 Connor Fund, Robert J. and Theresa W. RyanNoaber FoundationNIH: R01HL071158 CPRIT: RR190077 DON DNF (Diabetes Onderzoek Nederland [Diabetes Research Nederland]/diabetes fonds): 2020.10.002 Dutch Heart Foundation: 2021T055 NWO VIDI (Netherlands Organization for Scientific Research VIDI grant): 09150172210019 Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, ZonMw (The Netherlands Organization for Health Research and Development; ZonMw Open Competition): 09120011910025 NWO: KICH1.ST01.20.045 European UnionEuropean Research Council consolidator program: ERC2016COG724838 ANR (Agence Nationale de la Recherche [French National Research Agency]): 20-CE14-049-CHIC, 24-CE14-Glutacare Fondation de FranceUS Department of Veterans Affairs: BX000163 US Army Medical Research: HT94252410432 NASA (National Aeronautics and Space Administration)BARDA (Biomedical Advanced Research and Development Authority)USFDA (United States Food and Drug Administration): 80ARC023CA002
This work was partially supported by grants from the National Institutes of Health (NIH) to J.-i. Abe (HL-149303 and AI-156921), N.-T. Le (HL-134740 and HL-149303), X.H.T. Wehrens (HL-153350 and HL-160992), and A. Jain (HL157790) and from the Cancer Prevention and Research Institute of Texas (CPRIT) to J.-i. Abe and K. Schadler (RP190256). This work is also partially supported by the University of Texas MD Anderson Cancer Center Institutional Research Grant Program to S. Kotla. This research is supported, in part, by the MD Anderson Cancer Center Support Grant CA016672 (Medical Research Program: S.H. Lin, A. Deswal, and the flow cytometry core), National Cancer Institute's Research Specialist 1 R50 CA243707-01A1, and a Shared Instrumentation Award from the Cancer Prevention Research Institution of Texas (CPRIT), RP121010. J.L. Kirkland was supported by the US NIH (grants R37AG013925 and R33AG061456), the Hevolution Foundation (HF-GRO 1199148), the Connor Fund, Robert J. and Theresa W. Ryan, and the Noaber Foundation. Work in the laboratory of P.S. Brookes is funded by NIH R01HL071158. K.T. Nead is a CPRIT scholar in Cancer Research and is supported by the CPRIT grant RR190077. N.M.J. Hanssen is supported by a DON DNF (Diabetes Onderzoek Nederland [Diabetes Research Nederland]/diabetes fonds) grant 2020 (2020.10.002), Senior Clinical Dekker grant by the Dutch Heart Foundation (grant 2021T055), and an NWO VIDI (Netherlands Organization for Scientific Research VIDI grant) grant 2023 (09150172210019). M.P.J. de Winther is supported by Amsterdam University Medical Center, Amsterdam Cardiovascular Sciences, ZonMw (The Netherlands Organization for Health Research and Development; ZonMw Open Competition 09120011910025), NWO (Epi-Guide-Edit: KICH1.ST01.20.045), and the European Union (Doctoral Network MIRACLE [Multilevel Inflammatory Regulation in Cardiometabolic Disease]). Work in the laboratory of L. Yvan-Charvet is supported by grants from the European Research Council consolidator program (ERC2016COG724838), ANR (Agence Nationale de la Recherche [French National Research Agency])20-CE14-049-CHIC and 24-CE14-Glutacare), and Fondation de France. Work in the laboratory of I.M. Grumbach is also supported by the US Department of Veterans Affairs (BX000163). Work in the laboratory of A. Jain is also supported by the US Army Medical Research contract number HT94252410432; NASA (National Aeronautics and Space Administration), BARDA (Biomedical Advanced Research and Development Authority), NIH, and USFDA (United States Food and Drug Administration) under contract number 80ARC023CA002.
Language: English
Electronic publication date: 01/16/2025
Date published: 03/2025
Academic Unit: Cardiovascular Medicine; Radiation Oncology; Internal Medicine
Record Identifier: 9984775268602771

Metrics

6 Record Views

1 Times Cited - Web of Science